Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing

OKLAHOMA CITY, April 18, 2018 /PRNewswire/ -- Tetherex Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing novel selectin inhibitor products to treat thrombosis, inflammatory diseases and cancer, today announced that the company has successfully closed on a $50 million private placement of Series B preferred stock. Proceeds from the financing will be used to conduct a Phase 2 clinical trial evaluating the company's potential, first-in-class P-Selectin Glycoprotein Ligand-1 (PSGL-1) inhibitor candidate, SelK2, in the treatment of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery. In addition, Tetherex intends to use funds from the offering to conduct a second Phase 2 trial evaluating SelK2 in Crohn's disease or other inflammatory indication.

The funding was led by MPM Capital and a group of Oklahoma-based investors including Dr. Philip Jones, a member of the Tetherex Board of Directors.

"Our research suggests that SelK2 can broadly impact venous thrombosis, inflammation, and cancer where selectin/receptor-mediated cell adhesion has been shown to play a key pathologic role," said Dr. Scott Rollins, chairman and chief executive officer of Tetherex. "The additional investment by MPM Capital, a leading life sciences investor, and the overall success of this latest financing speak to the strength of the scientific data supporting the potential of SelK2 as a new, potentially first-in-class therapeutic option for several indications. We look forward to advancing SelK2 into Phase 2 clinical development later this year."  

About SelK2
SelK2 is a humanized monoclonal antibody that binds PSGL-1 and blocks its interactions with both the selectin family of molecules and chemokines involved in exaggerated and destructive inflammatory responses in thromboembolic and inflammatory diseases.

About Tetherex Pharmaceuticals, Inc.
Tetherex Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on development of selectin inhibitor therapeutics for the treatment of a broad range of diseases including thrombosis, inflammation and cancer. More information is available at www.tetherex.com


Dr. Scott Rollins                         

Paula Schwartz

Chairman and CEO                     

Managing Director

Tetherex Pharmaceuticals, Inc.    

Rx Communications Group, LLC





SOURCE Tetherex Pharmaceuticals, Inc.

These press releases may also interest you

at 01:13
Will invest $15 Million in Wealth Management over next one year  MobiKwik, India's leading full-stack fintech platform, announced its entry into the wealth management business with a 100% acquisition of Clearfunds, a leading online wealth...

at 01:01
After initially joining forces in February, Sam's Club and Instacart have announced the national expansion of their partnership to offer same-day delivery to more than half of all Sam's Clubs across the nation by the end of October. Just in time for...

at 01:01
SAP SE today announced its financial results for the third quarter ended September 30, 2018. "SAP is the fastest growing cloud company at scale in the enterprise software applications industry. Our growth drivers are...

at 01:00
Openbravo Delivers an End-to-end Solution with Cloud-ready Mobile POS and Omnichannel Capabilities for Retailers Through Interoperability With SAP IS Retail Openbravo today announced its Openbravo Commerce Suite solution has achieved certified...

at 01:00
A year after the company's successful first crowdinvesting campaign, the Munich-based mobility provider Sono Motors today announced the start of a second round of financing. The purpose of the campaign is to generate the capital needed for the...

at 01:00
RWS Entertainment Group (RWS), a full-service production company that creates award-winning custom entertainment, live events and brand experiences worldwide, announced a new partnership with Germany's largest amusement park, Europa-Park, for a...

News published on 18 april 2018 at 08:00 and distributed by: